

the trans of

The European & Developing Countries Clinical Trials Partnership (EDCTP) Plans and Progress



Neglected Infectious Diseases Stakeholders' Meeting

27-28 June 2013

Michael Makanga, MD PhD EDCTP Director S-S Cooperation





Mission and objectives of EDCTP



Mission

 To reduce the burden of poverty related diseases (HIV/AIDS, malaria, tuberculosis and NIDs) and generally improve the health of people living in developing countries

Objectives

 To accelerate research and development of new or improved interventions against these diseases through the coordination of the European member state national programmes working in **partnership** with sub-Saharan African countries and other global product development partners.



a the second of the

EDCTP Governance



General Assembly

Representatives and Deputies:

- Policy making body
- 16 European countries
- 4 African representatives:
- Regional Economic Communities
- African Union
- WHO/AFRO Regional Health Ministries
- Ministries of Finance/S&T

Strategic Advisory Committee

Scientific and strategic advisory body with membership from Africa, Europe and elsewhere

Executive Secretariat

Europe Office Africa Office



Working in partnerships





- Coordination of European national programmes
- Partnerships with sub-Saharan Africa
- Synergy among R&D international partners

Accelerated development of tools to fight povertyrelated diseases

Support to capacity development and networking



EDCTP scope



First in humans			Registration		
Discovery & Pre-clinical research	Pre-clinical Pre-rec		ıdies	Post-registration studies	Policy, Practice
Laboratory and animal testing	Phase I: Safety	Phase II: Safety & limited efficacy	Phase III: Safety & efficacy	Phase IV: Effectiveness Long-term safety Pharmacovigilance Optimisation Label expansion	

Disease profile: HIV/AIDS, TB, Malaria and NIDs

Interventions: Drugs, Vaccines, Microbicides and Diagnostics



EDCTP grants scheme




- Integrated Projects (Clinical trials; project management; capacity strengthening; and networking)
 - Senior Fellowships
 - Strategic Primer Grants (SPG)
 - Ethics and Regulatory Projects
 - Networks of Excellence
 - Member State Initiated projects (MSI)
 - Joint Call by Member States (JCMS)





Details on EDCTP grants



Prevention:


 Preparatory studies for vaccine development and vaccine development



the trans of

Clinical trials supported by EDCTP grants

Number of funded clinical trials





EDCTP Regional Networks of Excellence for clinical trials



Western Africa: WANETAM

Website: www.wanetam.org

Project Coordinator: Prof. Soleymane Mboup

- Burkina Faso
- •Mali Nigeria
- The Gambia Ghana
- Senegal
- Guinea-Bissau
- **Central Africa: CANTAM**

Website: www.cantam.org

Project Coordinator: Prof. Francine Ntoumi

Cameroon

• France

United States

- Congo, Republic of the • Germany
- Gabon

Eastern Africa: EACCR

Website: www.eaccr.org

Project Coordinator: Dr Pontiano Kaleebu

Germany

United States

 Sweden • United Kingdom

- Kenya
- Sudan
- Ethiopia
- Tanzania
- Uganda

Southern Africa: TESA

Website: www.tesafrica.org

Project Coordinator: Dr Alexander Pym

- Botswana
- Malawi
- Mozambigue
- South Africa
- Zambia
- France Germany Netherlands
- United Kingdom



• Zimbabwe



a second a second as any




Towards EDCTP2



Process towards an EDCTP2



- Independent external review, impact assessment and internal consultation recommended expansion of scope while maintaining focus
 - All phases of clinical trials (phase I-IV), special attention to phase III
 - Include Neglected Infectious Diseases (NIDs)
 - Collaboration with other DCs outside Africa when required
 - Health systems optimisation research
 - Closer collaboration with pharmaceutical industry and other like-minded organisation
 - Expected start in 2014.



On-going discussions with the European Commission and Member States on funding of EDCTP2 EDCTP2:

- Larger and more costly Phase III clinical trials
- Extension to NIDs, Phase IV



- Integrated Activities
- Participating States Initiated Activities
- Joint Activities



a the second of the

Integrated Activities/Projects



- Activities that are selected and funded by EDCTP from Participating States and EU contributions
- EDCTP-IS will manage the activities (Centralised peerreview, administration, evaluation and monitoring of grants)
- Horizon 2020 Rules of participation shall apply with any derogations



Participating States Initiated Activities (PSIA)



- Selected, funded and managed by EDCTP Participating States
 - Included in EDCTP annual workplan
 - With agreement of the EC and subject to the conditions, EDCTP2-IS may award co-funds from the EU contribution to increase its impact or expand its access to researchers from other EDCTP Participating States
 - EDCTP Participating States Rules of Participation will apply, with a minimal set of rules provided by EC/EDCTP



Joint Activities



- Undertaken by EDCTP-IS or any EDCTP Participating State with other countries or third parties
 - Consortium model of funding
 - Joint rules of participation will be established
 - Early involvement of EDCTP
 - Positive recommendation of the EDCTP Strategic Advisory Committee
 - Inclusion in annual workplans
 - Involvement of EDCTP in the grant management (review, monitoring)



Criteria for prioritisation of EDCTP activities



- Disease prevalence, burden and need taking into account status of interventions landscape
 - Product opportunities and following the course set in the Strategic Business Plan vis-à-vis the expanded remit i.e. NIDs and post registration programmes including effectiveness studies and pharmacovigilance
 - 3. Timing factor: balance between immediate and long-term priorities
 - 4. Balance among clinical trial phases: major investment focus III depending on existing global product portfolio.

Objectives of NIDs stakeholder



- Update on the global product portfolio for NIDs: post discovery translation and clinical development pipe and product development partners
- 2. Identify current research and capacity gaps in clinical development of the products in global portfolio for NIDs
- 3. Identify priority areas for future calls for proposals and alternative funding mechanisms
- 4. Identify interested and potential partners to collaborate with in the execution of future EDCTP activities
- 5. Collate views of EDCTP stakeholders to promote coordination and integration of national programmes of EDCTP European partner states, and to strengthen partnership with African researchers and other global partners.



a los a same o

Thank you







http://www.edctp.org